Immunochemistry and lung cancer: application in diagnosis, prognosis and targeted therapy
- PMID: 21734416
- DOI: 10.1159/000329064
Immunochemistry and lung cancer: application in diagnosis, prognosis and targeted therapy
Abstract
Immunochemistry is now an established ancillary technique in lung cancer diagnosis. Not only does it help in supporting the morphological diagnosis of malignancy, but its role now extends to the determination of cell lineage, ascertaining the primary site of tumour origin and contributing to decisions on prognosis and treatment. Early detection and confirmation of lung cancer facilitate early treatment decisions. Lung cancer management now has a multidisciplinary approach which includes cytopathologists and clinicians. Some clinicians may not understand what immunochemistry is and what its role is in lung cancer diagnosis, prognosis and therapy. The purpose of this paper is to define immunochemistry, on the background of basic respiratory airway epithelial structure and cancer biology, and discuss its application in the diagnosis, treatment and determination of prognosis of lung cancer.
Copyright © 2011 S. Karger AG, Basel.
Similar articles
-
Biological markers in lung cancer: A clinician's perspective.Cancer Biomark. 2010;6(3-4):123-35. doi: 10.3233/CBM-2009-0124. Cancer Biomark. 2010. PMID: 20660959 Review.
-
Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis.Expert Rev Mol Diagn. 2007 Jan;7(1):77-86. doi: 10.1586/14737159.7.1.77. Expert Rev Mol Diagn. 2007. PMID: 17187486 Review.
-
Advances in the diagnosis of lung cancer: contribution of molecular biology to bronchoscopic diagnosis.Curr Opin Pulm Med. 2010 Jul;16(4):315-20. doi: 10.1097/MCP.0b013e328337f938. Curr Opin Pulm Med. 2010. PMID: 20173641 Review.
-
Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?Lung Cancer. 2005 Jul;49(1):1-12. doi: 10.1016/j.lungcan.2004.12.008. Lung Cancer. 2005. PMID: 15949585 Review.
-
Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer.Biomed Pharmacother. 2007 Oct;61(9):515-9. doi: 10.1016/j.biopha.2007.08.005. Epub 2007 Sep 14. Biomed Pharmacother. 2007. PMID: 17913444 Review.
Cited by
-
USP5 knockdown alleviates lung cancer progression via activating PARP1-mediated mTOR signaling pathway.Biol Direct. 2023 Apr 14;18(1):16. doi: 10.1186/s13062-023-00371-z. Biol Direct. 2023. PMID: 37060095 Free PMC article.
-
Virtual biopsy through CT imaging: can radiomics differentiate between subtypes of non-small cell lung cancer?Radiol Med. 2025 May 22. doi: 10.1007/s11547-025-02022-x. Online ahead of print. Radiol Med. 2025. PMID: 40402434
-
TRF-16 Inhibits Lung Cancer Progression by Hindering the N6-Methyladenosine Modification of CPT1A mRNA.J Cell Mol Med. 2024 Dec;28(24):e70291. doi: 10.1111/jcmm.70291. J Cell Mol Med. 2024. PMID: 39679845 Free PMC article.
-
Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers.Cancer Res. 2017 Sep 15;77(18):5194-5206. doi: 10.1158/0008-5472.CAN-16-2072. Epub 2017 Jul 17. Cancer Res. 2017. PMID: 28716896 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical